%0 Journal Article
%T MGMT Gene Promoter Methylation Status ¨C Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas
%A FRANCESCA MICCI
%A IOANNIS PANAGOPOULOS
%A LENE E JOHANNESSEN
%A PETTER BRANDAL
%A SVERRE HEIM
%A TOR £żGE MYKLEBUST
%J Archive of "Cancer Genomics & Proteomics".
%D 2018
%R 10.21873/cgp.20102
%X Background: Although methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter predicts response to temozolomide in patients with glioblastoma, no consensus exists as to which assay is best for its detection. Materials and Methods: Methylation of MGMT promoter was examined by methylation-specific polymerase chain reaction (MSP), quantitative real-time MSP, methylation-sensitive high-resolution melting analysis, and two commercial pyrosequencing (PSQ) kits. Survival was compared among 48 patients with glioblastoma according to assay results. Results: Only PSQ and MSP significantly separated patients who benefited from temozolomide, with PSQ being the superior method. For PSQ analysis, the cut-off value that best correlated with prognostic outcome was 7% methylation of MGMT. Median survival in patients with MGMT promoter methylation above this cut-off value was 7.8 months longer compared to those with less than 7% methylation. Two-year overall survival for the two groups was 42% and 7.4%, respectively. Conclusion: PSQ is the method of choice for MGMT promoter methylation analysis in routine clinical practice
%K MGMT gene promoter
%K methylation
%K pyrosequencing
%K methylation-specific PCR
%K glioblastoma
%K overall survival
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299788/